Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Holdings Lifted by Connor Clark & Lunn Investment Management Ltd.

Key Points

• Connor Clark & Lunn Investment Management Ltd. increased its stake in Agios Pharmaceuticals by 207.6%, acquiring an additional 260,845 shares, bringing their total ownership to approximately 0.67% of the company.
• Agios Pharmaceuticals reported a loss of ($1.93) EPS for the last quarter, missing estimates, but had a revenue of $12.50 million, exceeding expectations.
• Insider trades included significant sales by CEO Brian Goff and Director David Scadden, with a total of 46,363 shares sold worth $1.62 million in the last quarter.

Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 207.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 386,523 shares of the biopharmaceutical company's stock after purchasing an additional 260,845 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.67% of Agios Pharmaceuticals worth $11,325,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Summit Investment Advisors Inc. lifted its position in shares of Agios Pharmaceuticals by 7.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock valued at $194,000 after acquiring an additional 394 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Agios Pharmaceuticals by 16.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock worth $105,000 after purchasing an additional 499 shares in the last quarter. Federated Hermes Inc. increased its stake in shares of Agios Pharmaceuticals by 4.4% during the 4th quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock worth $450,000 after purchasing an additional 582 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Agios Pharmaceuticals by 1.2% during the 4th quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company's stock worth $2,021,000 after purchasing an additional 708 shares in the last quarter. Finally, Gallagher Fiduciary Advisors LLC increased its stake in shares of Agios Pharmaceuticals by 7.6% during the 4th quarter. Gallagher Fiduciary Advisors LLC now owns 11,110 shares of the biopharmaceutical company's stock worth $365,000 after purchasing an additional 788 shares in the last quarter.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 1,780 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $59,701.20. Following the completion of the transaction, the chief financial officer owned 30,049 shares in the company, valued at approximately $1,007,843.46. This represents a 5.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David Scadden sold 1,400 shares of the company's stock in a transaction dated Thursday, July 10th. The stock was sold at an average price of $40.00, for a total transaction of $56,000.00. Following the completion of the transaction, the director owned 17,603 shares of the company's stock, valued at approximately $704,120. This trade represents a 7.37% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 57,448 shares of company stock worth $2,026,141. 4.30% of the stock is owned by company insiders.

Agios Pharmaceuticals Stock Up 0.5%

Shares of AGIO traded up $0.19 during midday trading on Friday, hitting $36.87. The company had a trading volume of 81,983 shares, compared to its average volume of 709,050. The company's 50 day moving average price is $36.45 and its 200 day moving average price is $32.75. The stock has a market cap of $2.14 billion, a price-to-earnings ratio of 3.35 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a 52 week low of $23.42 and a 52 week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. The business had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.46 million. Equities analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on AGIO. Wall Street Zen cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Scotiabank lowered their target price on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a research note on Monday, July 28th. Finally, Bank of America decreased their price target on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $56.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.